Breaking News
June 22, 2018 - Researchers report unusually high levels of herpesvirus in the brains of people with Alzheimer’s disease
June 22, 2018 - Theoretical models predict how juveniles evolve to be more susceptible than adults to infection
June 22, 2018 - USC study reveals how the cell launches emergency response to repair damaged DNA
June 22, 2018 - $1.9 million grant aims to enhance behavioral health services in community-based settings
June 22, 2018 - New 3D imaging technique could improve arthritis treatment
June 22, 2018 - Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy
June 22, 2018 - Polarized cells give the heart its fully developed form
June 21, 2018 - Stem cells appear to help fight obesity in animal models
June 21, 2018 - Harnessing Pediatric Cancer Genomic Data in the Cloud
June 21, 2018 - Training nursing students with cost-effective 3D-printed task trainers
June 21, 2018 - Study provides insight into how planned and spontaneous movements are processed in the brain
June 21, 2018 - Suicide Prevention | SAMHSA – Substance Abuse and Mental Health Services Administration
June 21, 2018 - From designer microbes to stem cells, researchers are investigating new strategies to treat bowel disease
June 21, 2018 - Study suggests state-of-the-art genomic testing for routine autopsy of stillbirths
June 21, 2018 - Christiana Care Health System opens first Epilepsy Monitoring Unit in Delaware
June 21, 2018 - CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
June 21, 2018 - Youths Treated for Non-Suicidal Self Harm at Increased Risk of Suicide Within a Year
June 21, 2018 - Pediatric kidney recipients often have subclinical inflammation
June 21, 2018 - OHSU Knight Cancer Institute Director wins 2018 Tang Prize in Biopharmaceutical Science
June 21, 2018 - Researchers study broader effects of neonics on wildlife
June 21, 2018 - Study provides new insight on how antibiotics affect the gut microbiome
June 21, 2018 - InHealth Technologies becomes exclusive distributor of RENÚ Voice, RENÚ Gel in the United States
June 21, 2018 - New analysis links higher BMI to lower breast cancer risk for younger women
June 21, 2018 - Interactive preclinical PET-MR workshop demonstrates benefits of multi-modality imaging
June 21, 2018 - Gene signature could improve early diagnosis of TB
June 21, 2018 - Psychiatric Drug Lithium Tied to Birth Defect Risk
June 21, 2018 - Preclinical study suggests ARID1a may be useful biomarker for immunotherapy
June 21, 2018 - Risks of cancer and mortality found to be lowest in light drinkers
June 21, 2018 - Fetal immune cells are fast-acting first responders to microbes in adulthood
June 21, 2018 - Researchers invent medical device for proliferation, differentiation of neural stem cells
June 21, 2018 - Study explores current understanding of human physiology, pathology, trauma and surgery in space
June 21, 2018 - Scientists explore interactions between chromosomes 12 and 17
June 21, 2018 - People with severe obesity constantly try to reduce or control their weight
June 21, 2018 - Breakthrough discovery reveals brain metals that may drive progression of Alzheimer’s disease
June 21, 2018 - New methods of fragment-based lead discovery to identify potential antibiotics
June 21, 2018 - Recovery and Treatment | NIH MedlinePlus the Magazine
June 21, 2018 - Study finds cell-free DNA profiling as versatile method to monitor UTIs
June 21, 2018 - ‘Hidden’ driver discovered that helps prime the anti-tumor immune response
June 21, 2018 - Groundbreaking discovery could be key to preventing cancer metastasis
June 21, 2018 - Impulse control disorders found to be more common in people taking Parkinson’s drugs
June 21, 2018 - Study finds possible link between Type 2 diabetes and common white pigment
June 21, 2018 - Most emergency department patients wish to be involved in medical decision-making
June 21, 2018 - Study highlights growing problem of ‘iPad neck’ among young adults and women
June 21, 2018 - UT Southwestern scientists identify gene mutation linked with perplexing brain condition
June 21, 2018 - Probiotics could cut age-related bone loss in elderly women
June 21, 2018 - New study sheds light on role of vitamin D in healthy pregnancy
June 21, 2018 - Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache
June 21, 2018 - Unlocking the secrets of HIV’s persistence
June 21, 2018 - New guidelines recommend newborns with Down’s syndrome to receive leukemia test
June 21, 2018 - BetterYou’s new Magnesium Bone Lotion helps maximize bone health
June 21, 2018 - UH scientist receives grant to examine understudied part of glaucoma
June 21, 2018 - Lifestyle intervention could normalize unhealthy behaviors that lead to cancer, chronic disease
June 21, 2018 - Combining two anti-malarial vaccines could greatly reduce number of infections
June 21, 2018 - By 2030, prostate and lung cancers expected to be most common cancers among HIV population
June 21, 2018 - Researchers evaluate patient satisfaction and well-being after breast reconstruction
June 21, 2018 - Combining stem cell technology and artificial intelligence to diagnose genetic cardiac diseases
June 21, 2018 - Monash study reveals why older people have reduced immune responses to cancer therapy
June 21, 2018 - Researchers develop new microscope system that can image living tissue in real time
June 21, 2018 - Long-term estrogen therapy alters microbial composition and activity in the gut
June 21, 2018 - Study points to dangers of feeding non-dairy drink to infants
June 21, 2018 - Cannabis Use Linked to Psychosis Symptoms in Adolescents
June 21, 2018 - Inadequate sleep could cost countries billions
June 21, 2018 - Inhibiting epigenetic proteins with drugs could prevent development of breast cancer
June 21, 2018 - Study identifies factors that contribute to vaginal dryness
June 21, 2018 - Researchers employ nucleotide-based gene silencing to mitigate common ataxia
June 21, 2018 - New tool determines best treatment plan for adults with severe asthma
June 21, 2018 - Identifying gene variants that contribute to ovarian reserve may improve female fertility
June 21, 2018 - Religious involvement has no significant effect on misuse of prescription opioids, study finds
June 21, 2018 - Researchers characterize key signaling network that drives growth of triple negative breast cancers
June 21, 2018 - AHA: Big Weight Gain in 1st Pregnancy Could Boost Preeclampsia Risk
June 21, 2018 - How vaping helps even hardened smokers quit
June 21, 2018 - Gaming disorder an official disease condition says WHO
June 21, 2018 - Oxygen consumption in human BAT increases after a meal, shows research
June 21, 2018 - Research finds addictions to be diseases of the brain, not criminal behavior or personality disorders
June 21, 2018 - New study is testing safety and efficacy of glycoside in breaking up kidney stones
June 21, 2018 - Biosimilar competition may offer hope for cheaper, better psoriasis treatments in the future
June 21, 2018 - Cells form cage-like structures that trap viruses
June 21, 2018 - Wound protector use linked to significant reduction in surgical site infection
June 21, 2018 - African Americans and Latinos are more likely to be at risk for depression than Whites
June 21, 2018 - Genome study presents new way to track historical demographics of US populations
Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva

Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva

image_pdfDownload PDFimage_print

MONTREAL, Dec. 12, 2017 (GLOBE NEWSWIRE) — Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced the start of the MOVE Trial, its Phase 3 registration study evaluating the safety and efficacy of palovarotene for the treatment of patients with fibrodysplasia ossificans progressiva (FOP). Palovarotene, Clementia’s lead product candidate, is a retinoic acid receptor gamma agonist (RARγ) being investigated as a treatment for patients with ultra-rare and debilitating bone diseases, including FOP and multiple osteochondromas (MO), as well as other diseases.

“FOP is a rare, devastating, and debilitating disease for patients. It causes great hardship to families and caregivers. We are very excited to be part of this first-ever multicenter Phase 3 clinical trial for patients with FOP, for which there are no approved treatments,” said Edward Hsiao, M.D., Ph.D., associate professor in endocrinology and the Institute for Human Genetics at the University of California San Francisco (UCSF) School of Medicine, and one of the principal investigators of the MOVE Trial. “Palovarotene has shown promise in its Phase 2 program. Our team looks forward to working with patients and our fellow investigators from around the world to complete this important study.”

UCSF is the first site to enroll a patient in the MOVE Trial, which will be conducted at approximately 20 centers in 16 countries around the world (Argentina, Australia, Brazil, Canada, France, Germany, Italy, Japan, Netherlands, Russia, South Africa, South Korea, Spain, Sweden, United Kingdom and United States). Additional sites are expected to begin enrolling patients in the coming months, with completion of enrollment expected by the end of 2018.

“The initiation of this study is a landmark event for Clementia, fully transitioning us into a late-stage clinical organization,” commented Donna Grogan, M.D., chief medical officer of Clementia. “To date we have treated over fifty FOP patients in our Phase 2 clinical program, and we are encouraged by palovarotene’s safety profile and the efficacy data showing meaningful reductions in new heterotopic ossification (HO) volume following a flare-up.” HO is a hallmark sign of FOP, in which bone grows where it should not, outside the skeleton and in abnormal places, such as muscles, tendons and soft tissue in patients with FOP.

“Palovarotene is rapidly advancing through clinical development and could be the first treatment to be approved for patients with FOP,” said Clarissa Desjardins, Ph.D., chief executive officer of Clementia. “Our team is motivated by the medical need for patients with FOP and wishes to thank the patients, their families and caregivers, and the investigators around the world who have been working hand-in-hand with us over the past three years to advance palovarotene to this important milestone.”

About the Phase 3 MOVE Trial

All patients in the MOVE Trial receive a single daily dose of palovarotene, with increased dosing at the time of a flare-up. Data from the FOP patients in Clementia’s Natural History Study (NHS) will serve as the control. Patients will be treated with palovarotene for 24 months, with three planned interim analyses. The first interim analysis will occur when the first 35 patients have completed their one-year CT scans, with the next two interim analyses coming 6 and 12 months afterwards. Clementia expects top-line results from the study in late 2020, with the first interim readout expected in early 2019.

The primary efficacy endpoint of the MOVE Trial is the annualized change in new HO volume as assessed by low-dose WBCT scan (excluding head) compared to untreated patients from the NHS. Secondary endpoints include the proportion of patients with any new HO, the change in the number of body regions with new HO, the proportion of patients reporting flare-ups and the rate of flare-up occurrence. Exploratory endpoints include functional assessments of joint function and changes in patient-reported physical function. Safety evaluations include adverse events, assessments of growth in children, clinical laboratory tests and vital signs. Full details of the study can be found at www.clinicaltrials.gov, NCT03312634.

About Palovarotene

Palovarotene is a retinoic acid receptor gamma agonist (RARγ) being investigated as a treatment for patients with ultra-rare and debilitating bone diseases, including fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), and other diseases with high medical need. Preliminary Phase 2 data in patients with FOP mirror the decrease in heterotopic ossification (HO) volume observed in mouse models of FOP and support the initiation of the confirmatory Phase 3 MOVE Trial. Palovarotene also inhibits the formation of osteochondromas (OCs) in mouse models of multiple exostoses, supporting development in the MO indication. Palovarotene has received Orphan Drug designation for FOP and MO from the U.S. Food and Drug Administration (FDA). In addition, palovarotene has been granted Fast Track and Breakthrough Therapy designations for FOP from the FDA, and was granted orphan status for the treatment of FOP in the EU.

About Fibrodysplasia Ossificans Progressiva (FOP)

FOP is a rare, severely disabling disorder characterized by heterotopic ossification (HO), or bone that forms outside the normal skeleton in muscles, tendons or soft tissue. In FOP, HO progressively restricts movement by locking joints leading to a cumulative loss of function, progressive disability, and increased risk of early death. FOP is caused by a mutation in the ACVR1 gene, resulting in excess signaling in the bone morphogenetic pathway, a key pathway controlling bone growth and development, by way of both ligand-dependent and independent mechanisms. There are currently no approved treatments for FOP.

About Clementia Pharmaceuticals Inc.

Clementia is a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company’s lead candidate palovarotene, a novel RARγ agonist, is currently being evaluated in the Phase 3 MOVE Trial to treat fibrodysplasia ossificans progressiva (FOP), with additional clinical studies planned in multiple osteochondromas (MO, also known as hereditary multiple exostoses) and other diseases. For more information, please visit www.clementiapharma.com.

UC Disclaimer

The information stated above was prepared by Clementia Pharmaceuticals Inc. to report on research conducted on its product and reflects solely the opinion of Clementia. Nothing in this statement shall be construed to imply any support or endorsement of Clementia, or any of its products, by The Regents of the University of California, its officers, agents and employees.

Cautionary Note Regarding Forward-Looking Statements

This press release may include “forward-looking statements” within the meaning of the applicable securities laws. Each forward-looking statement contained in this press release is subject to known and unknown risks and uncertainties and other unknown factors that could cause actual results to differ materially from historical results and those expressed or implied by such statement. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “will,” or “plans” to be uncertain and forward-looking. Applicable risks and uncertainties include, among others, our ability to generate revenue and become profitable; the risks related to our heavy reliance on palovarotene, our only current product candidate; the risks associated with the development of palovarotene and any future product candidate, including the demonstration of efficacy and safety; our heavy dependence on licensed intellectual property, including our ability to source and maintain licenses from third-party owners; as well as the risks identified under the heading “Risk Factors” in our Prospectus on Form 424(b) filed with the Securities and Exchange Commission (“SEC”), as well as the other information we file with the SEC or on SEDAR. We caution investors not to rely on the forward-looking statements contained in this press release when making an investment decision in our securities. You are encouraged to read our filings with the SEC or on SEDAR, available at www.sec.gov or www.sedar.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this press release, and we undertake no obligation to update or revise any of these statements, whether as a result of new information, future events or otherwise, except as required by law.

Source: Clementia Pharmaceuticals Inc.

Posted: December 2017

Tagged with:

About author

Related Articles